---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000038"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:49:25.510161+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume

## Summary
- FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.
- Enrollment reinitiated in Phase 1a/1b for relapsed/refractory B-cell malignancies.
- Prioritizing aggressive NHL (DLBCL, MCL) where durable complete responses previously observed.
- Patients currently enrolled and deriving benefit from prior process may continue treatment.
- Company cites accelerated interest from ASH data and Science publication on BTK degrader programs.

## SEC filing metadata
- accession: 0001549595-24-000038
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000038/0001549595-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000038/nrix-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000038
- JSON: https://secwatch.observer/filing/0001549595-24-000038.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.